The Search for ‘Evolution-Proof’ Antibiotics

Trends in Microbiology

Volumn 26, Issue 6, 2018, Pages 471-483

  Bell, Graham ^a,b   MacLean, Craig ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; ANTIINFECTIVE AGENT; DEPSIPEPTIDE; TEIXOBACTIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL METABOLISM; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM MUTANT; DRUG EFFICACY; EPIDEMIC; GENE MUTATION; GENETIC VARIATION; HORIZONTAL GENE TRANSFER; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; MICROBIAL DIVERSITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; MOLECULAR EVOLUTION; NATURAL SELECTION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; BACTERIUM; DRUG DEVELOPMENT; DRUG EFFECT; GENETICS; METAGENOMICS; MUTATION;

ANTI-BACTERIAL AGENTS; BACTERIA; DEPSIPEPTIDES; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; EVOLUTION, MOLECULAR; METAGENOMICS; MUTATION;

EID: 85035241821     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2017.11.005     Document Type: Review

References (55)

1. Ling, L.L., et al. A new antibiotic kills pathogens without detectable resistance. Nature 517 (2015), 455–459.
2. Schmieder, R., Edwards, R., Insights into antibiotic resistance through metagenomic approaches. Future Microbiol. 7 (2012), 73–89.
3. Baym, M., et al. Multidrug evolutionary strategies to reverse antibiotic resistance. Science, 351, 2016, aad3292.
4. Allen, R.C., et al. Targeting virulence: can we make evolution-proof drugs?. Nat. Rev. Microbiol. 12 (2014), 300–308.
5. Ross-Gillespie, A., Kummerli, R., ‘Evolution-proofing’ antibacterials. Evol. Med. Public Health 2014 (2014), 134–135.
6. Blair, J.M., et al. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 13 (2015), 42–51.
7. Walsh, C., Antibiotics: Actions, Origins, Resistance. 2003, ASM Press.
8. Andersson, D.I., The biological cost of mutational antibiotic resistance: any practical conclusions?. Curr. Opin. Microbiol. 9 (2006), 461–465.
9. Andersson, D.I., Hughes, D., Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat. Rev. Microbiol. 8 (2010), 260–271.
10. Vogwill, T., MacLean, R.C., The genetic basis of the fitness costs of antimicrobial resistance: a meta-analysis approach. Evol. Appl. 8 (2015), 284–295.
11. Sancho-Vaello, E., Zeth, K., Antimicrobial peptides: has their time arrived?. Future Microbiol. 10 (2015), 1103–1106.
12. Zasloff, M., Antimicrobial peptides of multicellular organisms. Nature 415 (2002), 389–395.
13. Andersson, D.I., et al. Mechanisms and consequences of bacterial resistance to antimicrobial peptides. Drug Resist. Updat. 26 (2016), 43–57.
14. Bauer, M.E., Shafer, W.M., On the in vivo significance of bacterial resistance to antimicrobial peptides. Biochim. Biophys. Acta 1848 (2015), 3101–3111.
15. Perron, G.G., et al. Experimental evolution of resistance to an antimicrobial peptide. Proc. Biol. Sci. 273 (2006), 251–256.
16. Campbell, E.A., et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104 (2001), 901–912.
17. Comas, I., et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 44 (2011), 106–110.
18. Farhat, M.R., et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat. Genet. 45 (2013), 1183–1189.
19. Gagneux, S., et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312 (2006), 1944–1946.
20. Vogwill, T., et al. Testing the role of genetic background in parallel evolution using the comparative experimental evolution of antibiotic resistance. Mol. Biol. Evol. 31 (2014), 3314–3323.
21. Qi, Q., et al. Linking system-wide impacts of RNA polymerase mutations to the fitness cost of rifampin resistance in Pseudomonas aeruginosa. mBio, 5, 2014, e01562.
22. Luria, S.E., Delbruck, M., Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28 (1943), 491–511.
23. Baquero, F., Coque, T.M., Widening the spaces of selection: evolution along sublethal antimicrobial gradients. mBio, 5, 2014, e02270.
24. Gullberg, E., et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog., 7, 2011, e1002158.
25. MacLean, R.C., Buckling, A., The distribution of fitness effects of beneficial mutations in Pseudomonas aeruginosa. PLoS Genet., 5, 2009, e1000406.
26. Jochumsen, N., et al. The evolution of antimicrobial peptide resistance in Pseudomonas aeruginosa is shaped by strong epistatic interactions. Nat. Commun., 7, 2016, 13002.
27. Ferrero, L., et al. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39 (1995), 1554–1558.
28. Lee, H., et al. Rate and molecular spectrum of spontaneous mutations in the bacterium Escherichia coli as determined by whole-genome sequencing. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E2774–E2783.
29. Drake, J.W., A constant rate of spontaneous mutation in DNA-based microbes. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 7160–7164.
30. Drake, J.W., et al. Rates of spontaneous mutation. Genetics 148 (1998), 1667–1686.
31. Iredell, J., et al. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. BMJ, 352, 2016, h6420.
32. Pitout, J.D., et al. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob. Agents Chemother. 59 (2015), 5873–5884.
33. Stoesser, N., et al. Evolutionary history of the global emergence of the Escherichia coli epidemic clone ST131. mBio, 7, 2016, e02162.
34. Chambers, H.F., Deleo, F.R., Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7 (2009), 629–641.
35. Ito, T., et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45 (2001), 1323–1336.
36. Forsberg, K.J., et al. The shared antibiotic resistome of soil bacteria and human pathogens. Science 337 (2012), 1107–1111.
37. Perron, G.G., et al. Functional characterization of bacteria isolated from ancient arctic soil exposes diverse resistance mechanisms to modern antibiotics. PLoS One, 10, 2015, e0069533.
38. Sommer, M.O.A., et al. Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 325 (2009), 1128–1131.
39. Baquero, F., et al. Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance. Antimicrob. Agents Chemother. 55 (2011), 3649–3660.
40. Allen, H.K., et al. Call of the wild: antibiotic resistance genes in natural environments. Nat. Rev. Microbiol. 8 (2010), 251–259.
41. D'Costa, V.M., et al. Antibiotic resistance is ancient. Nature 477 (2011), 457–461.
42. Morar, M., Wright, G.D., The genomic enzymology of antibiotic resistance. Annu. Rev. Genet. 44 (2010), 25–51.
43. Low-Décarie, E., et al. Communities that thrive in extreme conditions captured from a freshwater lake. Biol. Lett., 12, 2016 20160562.
44. Mideo, N., et al. Linking within- and between-host dynamics in the evolutionary epidemiology of infectious diseases. Trends Ecol. Evol. 23 (2008), 511–517.
45. Park, M., et al. Multiple scales of selection influence the evolutionary emergence of novel pathogens. Philos. Trans. R. Soc. Lond. B Biol. Sci., 368, 2013 20120333.
46. Webb, G.F., et al. A model of antibiotic-resistant bacterial epidemics in hospitals. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 13343–13348.
47. Drlica, K., The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52 (2003), 11–17.
48. Day, T., et al. Is selection relevant in the evolutionary emergence of drug resistance?. Trends Microbiol. 23 (2015), 126–133.
49. McNally, A., et al. Combined analysis of variation in core, accessory and regulatory genome regions provides a super-resolution view into the evolution of bacterial populations. PLoS Genet., 12, 2016, e1006280.
50. Holden, M.T.G., et al. A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic. Genome Res. 23 (2013), 653–664.
51. Anderson, R.M., May, R.M., Population biology of infectious diseases: Part I. Nature 280 (1979), 361–367.
52. McCallum, H., et al. How should pathogen transmission be modelled?. Trends Ecol. Evol. 16 (2001), 295–300.
53. Mishra, R.P., et al. Vaccines and antibiotic resistance. Curr. Opin. Microbiol. 15 (2012), 596–602.
54. Haldane, J.B.S., A mathematical theory of natural and artificial selection, Part V: Selection and mutation. Math. Proc. Camb. Philos. Soc. 23 (2008), 838–844.
55. Crow, J.F., Kimura, M., An Introduction to Population Genetics Theory. 1970, Harper & Row Figure Legends.